Cargando…

In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib

BACKGROUND: Bosutinib is a recently approved ABL inhibitor. In spite of the well-documented effectiveness of BCR-ABL inhibitors in treating chronic myeloid leukemia, development of resistance is a continuous clinical challenge. Transporters that facilitate drug uptake and efflux have been proposed a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Redaelli, Sara, Perini, Pietro, Ceccon, Monica, Piazza, Rocco, Rigolio, Roberta, Mauri, Mario, Boschelli, Frank, Giannoudis, Athina, Gambacorti-Passerini, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4491863/ https://www.ncbi.nlm.nih.gov/pubmed/26149173 http://dx.doi.org/10.1186/s13045-015-0179-4

Ejemplares similares

Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma
por: Redaelli, Sara, et al.
Publicado: (2016)

An Imatinib–non‐responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization
por: Crespiatico, Ilaria, et al.
Publicado: (2019)

Pregnancy outcomes in patients treated with bosutinib
por: Cortes, Jorge E, et al.
Publicado: (2020)

Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling
por: Ceccon, Monica, et al.
Publicado: (2018)

NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
por: Mologni, Luca, et al.
Publicado: (2015)

Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia
por: Khoury, H J, et al.
Publicado: (2018)

Relationship between molecular response and quality of life with bosutinib or imatinib for chronic myeloid leukemia
por: Brümmendorf, Tim H., et al.
Publicado: (2020)

Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells
por: Mologni, Luca, et al.
Publicado: (2012)

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK
por: Fontana, Diletta, et al.
Publicado: (2015)

FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery
por: Piazza, Rocco, et al.
Publicado: (2012)

Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review
por: Cortes, Jorge E., et al.
Publicado: (2018)

Molecular Pathogenesis of BCR-ABL-Negative Atypical Chronic Myeloid Leukemia
por: Fontana, Diletta, et al.
Publicado: (2021)

Single‐center study on SARS‐CoV‐2 infection in patients affected by CML: Vaccination status and bosutinib therapy as possible protective factors for hospitalization
por: Civettini, Ivan, et al.
Publicado: (2023)

PB1976: SINGLE CENTER STUDY ON SARS-COV-2 INFECTION IN PATIENTS AFFECTED BY CML: VACCINATION STATUS AND BOSUTINIB THERAPY AS POSSIBLE PROTECTIVE FACTORS FOR HOSPITALIZATION.
por: Civettini, Ivan, et al.
Publicado: (2023)

PB1966: THE EFFECT OF BODY MASS INDEX ON THE SAFETY OF BOSUTINIB IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A POST HOC POOLED DATA ANALYSIS
por: Isfort, Susanne, et al.
Publicado: (2023)

Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
por: Inzoli, Elena, et al.
Publicado: (2022)

Control of mammary tumor differentiation by SKI-606 (bosutinib)
por: Hebbard, Lionel, et al.
Publicado: (2010)

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
por: Cortes, Jorge E., et al.
Publicado: (2016)

Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases
por: Spinelli, Roberta, et al.
Publicado: (2013)

Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases
por: Spinelli, Roberta, et al.
Publicado: (2014)

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
por: Brümmendorf, Tim H, et al.
Publicado: (2015)

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2014)

Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study
por: Cortes, Jorge E., et al.
Publicado: (2023)

CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data
por: Piazza, Rocco, et al.
Publicado: (2013)

Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
por: Brümmendorf, Tim H., et al.
Publicado: (2015)

Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors
por: Gambacorti‐Passerini, Carlo, et al.
Publicado: (2015)

Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma
por: Arosio, Giulia, et al.
Publicado: (2021)

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
por: Cortes, Jorge E., et al.
Publicado: (2018)

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
por: Hochhaus, Andreas, et al.
Publicado: (2020)

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2018)

Long‐term patient‐reported outcomes from an open‐label safety and efficacy study of bosutinib in Philadelphia chromosome–positive chronic myeloid leukemia patients resistant or intolerant to prior therapy
por: Kantarjian, Hagop M., et al.
Publicado: (2017)

Lapatinib potentiates cytotoxicity of YM155 in neuroblastoma via inhibition of the ABCB1 efflux transporter
por: Radic-Sarikas, Branka, et al.
Publicado: (2017)

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial
por: Brümmendorf, Tim H., et al.
Publicado: (2022)

Rheumatoid Arthritis Disease Activity Is Determinant for ABCB1 and ABCG2 Drug-Efflux Transporters Function
por: Atisha-Fregoso, Yemil, et al.
Publicado: (2016)

VERSO: A comprehensive framework for the inference of robust phylogenies and the quantification of intra-host genomic diversity of viral samples
por: Ramazzotti, Daniele, et al.
Publicado: (2021)

Bosutinib for Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2015)

Bafetinib (INNO-406) reverses multidrug resistance by inhibiting the efflux function of ABCB1 and ABCG2 transporters
por: Zhang, Yun-Kai, et al.
Publicado: (2016)

Long Range Communication between the Drug-Binding Sites and Nucleotide Binding Domains of the Efflux Transporter ABCB1
por: Clouser, Amanda F., et al.
Publicado: (2022)

Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain
por: Levinson, Nicholas M., et al.
Publicado: (2012)

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up
por: Gambacorti-Passerini, Carlo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_t4pvd4i8aq96au6r2cc2resrmi